

Table 14-3.02
Primary Endpoint Analysis: CIBIC+ - Summary at Week 24 - LOCF

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Week 24			
n	79	81	74
Mean (SD)	4.3 (0.77)	4.2 (0.79)	4.3 (0.81)
Median (Range)	4.0 (2;6)	4.0 (2;6)	4.0 (3;6)
p-value(Dose Response) [1] [2]			0.960
p-value(Xan - Placebo) [1] [3]		0.489	0.799
Diff of LS Means (SE)		-0.1 (0.13)	0.0 (0.13)
95% CI		(-0.3;0.2)	(-0.2;0.3)
p-value(Xan High - Xan Low) [1] [3]			0.349
Diff of LS Means (SE)			0.1 (0.13)
95% CI			(-0.1;0.4)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006